In adults, acute lymphoblastic leukemia (ALL) is an aggressive malignancy that, while initially highly responsive to chemotherapy, has a high relapse rate and poor survival. The role of allogeneic transplantation in ALL, the use of pediatric strategies in adolescents and young adults, the administration of rituximab for CD20-positive B-lineage ALL, tyrosine kinase inhibitors for Philadelphia ch...

Leukemia is the most common childhood malignancy and acute lymphoblastic leukemia (ALL) represents the largest sub-type. Despite remarkable improvements over the last 40 years, standard therapy fails in 10-20% of newly diagnosed patients. Survival for children with relapsed ALL is poor, and the development and implementation of novel therapeutic strategies in pediatric ALL are critical to furth...

The success in pediatric oncology and hematology diseases treatment opened the way to cure more than 90 % of patients with leukemias lemphomas. ability share an achievements modern paediatric hematology, find actual directions development, permit specialists from every corner world communicate discuss most difficult aspects diagnosis malignancies – basis International Society Paediatric Oncolog...

Abstract Bispecific T-cell engagers (BiTEs) redirect endogenous populations to cells expressing tumour associated antigens induce cell killing. This inherently relies upon a cytotoxic population that is able be recruited. In many cancers, immune checkpoints and other immunosuppressive factors in the microenvironment lead of anergic T-cells which cannot redirected killing thus impede efficacy Bi...

New genetic markers for adult acute lymphoblastic leukemia (ALL) have been found to have prognostic impact, such as the lymphoid transcription factor gene IKZF1 alterations, which are associated with a high rate of leukemic relapse in B-ALL. Although complete remission rates by induction chemotherapy in ALL are now high, the long-term survival is still disappointing. Improvements in the surviva...